近日，华东医药（000963）股份有限公司全资子公司杭州中美华东制药有限公司美国合作方 Arcutis Biotherapeutics，Inc. （NASDAQ：ARQT，以下简称“Arcutis”)对外宣布，美国食品药品监督管理局（FDA）受理了其ZORYVE （罗氟司特）乳膏（0.05%） 的补充新药申请 （sNDA），用于 2 至 5 岁儿童轻度至中度特应性皮炎（AD）的局部治疗。根据《处方 ...

Formation of keratinized scales Scales are formed by folds of the integument. Raised and depressed areas appear in the integument. Each bump consists of epidermis with the dermis underneath it and is ...

A total of 1,337 children and adults with AD were enrolled in the INTEGUMENT-1 (n=654) and INTEGUMENT-2 (n=683) trials. When compared with control, significantly more patients treated with ...

Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional ...

(RTTNews) - Arcutis Biotherapeutics, Inc.?(ARQT), Monday announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 randomized vehicle ...